Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.38 |
| ▸ | FABP7 | O15540 | 2/20 | 0.38 |
| ▸ | PREP | P48147 | 3/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29398515 | 1.00 | KLK7 (0.41) | KLK7KLK5F2ALDH1A1SMN1; SMN2 | |
| SCHEMBL25400415 | 1.00 | KLK7 (0.41) | KLK7KLK5F2ALDH1A1SMN1; SMN2 | |
| SCHEMBL31603928 | 0.85 | KMT2A (0.46) | F2FKBP1AKMT2A | |
| SCHEMBL29384614 | 0.84 | ALDH1A1 (0.43) | KLK7KLK5F2ALDH1A1SMN1; SMN2 | |
| SCHEMBL15083158 | 0.83 | PDK2 (0.45) | F2ALDH1A1SMN1; SMN2FABP5FABP7 | |
| SCHEMBL15803221 | 0.83 | PDK2 (0.45) | F2ALDH1A1SMN1; SMN2FABP5FABP7 | |
| SCHEMBL14417972 | 0.82 | ALDH1A1 (0.46) | F2ALDH1A1SMN1; SMN2FKBP1AKMT2A | |
| SCHEMBL1002927 | 0.82 | ALDH1A1 (0.58) | F2ALDH1A1SMN1; SMN2FABP5FABP7 | |
| SCHEMBL118354 | 0.82 | ALDH1A1 (0.58) | F2ALDH1A1SMN1; SMN2FABP5FABP7 | |
| SCHEMBL119560 | 0.82 | ALDH1A1 (0.58) | F2ALDH1A1SMN1; SMN2FABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110183532-B | Process method for synthesizing bivalirudin protected pentapeptide fragments by mass high-efficiency liquid phase method | 济南爱思医药科技有限公司 | 2023-06-30 | — | — | CN | claimed |
| CN-110183532-A | A kind of high-volume high-efficient liquid phase technique synthesis bivalirudin protects the process of five peptide fragments | 济南爱思医药科技有限公司 | 2019-08-30 | — | — | CN | claimed |
| US-20230293716-A1 | ELASTASE-SUBSTRATE, PEPTIDE LINKER IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293716-A1 | ELASTASE-SUBSTRATE, PEPTIDE LINKER IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| CN-110183532-B | Process method for synthesizing bivalirudin protected pentapeptide fragments by mass high-efficiency liquid phase method | 济南爱思医药科技有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-115996756-A | Elastase substrate peptide linker immunoconjugates and uses thereof | 博尔特生物治疗药物有限公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-110183532-A | A kind of high-volume high-efficient liquid phase technique synthesis bivalirudin protects the process of five peptide fragments | 济南爱思医药科技有限公司 | 2019-08-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293716-A1 | ELASTASE-SUBSTRATE, PEPTIDE LINKER IMMUNOCONJUGATES, AND USES THEREOF | SERPINB1, ELANE, CELA1 | KLK7 102/4885KLK5 144/4885F2 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.